Year: 2025

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly reduced oral corticosteroid and rescue medicine use compared to placebo Data support the potential of Dupixent to be the first and only targeted medicine to treat bullous pemphigoid, a skin disease with underlying type 2 inflammation; regulatory submissions are under review in the U.S. and the European Union TARRYTOWN, N.Y. and PARIS, March 08, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent® (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP). The data were shared...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AADFive times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly reduced oral corticosteroid and rescue medicine use compared to placeboData support the potential of Dupixent to be the first and only targeted medicine to treat bullous pemphigoid, a skin disease with underlying type 2 inflammation; regulatory submissions are under review in the US and the EUParis and Tarrytown, NY, March 8, 2025. Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a late-breaking oral presentation...

The Board of Directors of Kaldalón hf. hereby announces that the Annual General Meeting of the company will be held on Wednesday, April 3, 2025, at 16:00 GMT. The meeting will be held at Reykjavík Natura, Nauthólsvegur 52, 101 Reykjavík. Enclosed is the agenda for the Annual General Meeting.  Meeting documents and further information concerning the meeting is available on the website kaldalon.is/adalfundur2025.  

ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and systemic lupus Phase 2 OLE data of ESK-001 at 40 mg BID demonstrated sustained or increasing clinical responses through week 52 on PASI 90, PASI 100, and sPGA 0 ESK-001 was generally well-tolerated at one year, with no new safety findings Data further support ESK-001’s potential to offer a highly differentiated and best-in-class treatment option for people with moderate-to-severe plaque psoriasis Phase 3 ONWARD program ongoing with topline data expected in Q1 2026SOUTH SAN FRANCISCO, Calif., March 08, 2025 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes...

For Immediate Release – Not for Dissemination in the United States or through U.S. Newswire Services Greenville, South Carolina, March 07, 2025 (GLOBE NEWSWIRE) — ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) is pleased to announce that it has closed its previously announced non-brokered private placement (the “Offering”) for gross proceeds of C$800,000, through the sale of 10,000,0000 units of the Company (the “Units”) at a price of C$0.08 per Unit. Each Unit consists of one class A subordinate voting share in the capital of the Company (a “Share”) and one Share purchase warrant (a “Warrant”). Each Warrant entitles the holder thereof to purchase an additional Share at a price of C$0.12 for 24 months from issuance, provided that if at any time after the closing date the daily volume weighted average trading price of the...

TAMPA, Fla., March 07, 2025 (GLOBE NEWSWIRE) — Better Choice Company Inc. (NYSE: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, today announced it will host a conference call and webcast on Thursday, March 27, 2025, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year 2024 and provide a business update. Additionally, we have filed a supplemental proxy statement. This filing is part of our ongoing commitment to transparency and shareholder engagement. The supplemental proxy statement can be accessed here. Conference Call and Webcast Information:Event: Fourth Quarter and Full Year 2024 Financial Results Conference CallDate: Thursday, March 27, 2025Time: 4:30 p.m. Eastern TimeLive Call: 1-888-348-8935 or 1-412-317-0454Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1710449&tp_key=75345a2769 For...

KIRKLAND, Wash., March 07, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS) (“Kestra”), a wearable medical device and digital healthcare company, announced today the closing of its upsized initial public offering of 11,882,352 common shares at a public offering price of $17.00 per share. The total gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Kestra, were approximately $202 million. All of the common shares were offered by Kestra. Kestra’s common shares began trading on the Nasdaq Global Select Market on March 6, 2025, under the ticker symbol “KMTS”. BofA Securities, Goldman Sachs & Co. LLC and Piper Sandler acted as lead bookrunners for the offering. Wells Fargo Securities and Stifel acted as bookrunners...

CARLSBAD, Calif., March 07, 2025 (GLOBE NEWSWIRE) — AppTech Payments Corp. (“AppTech or the “Company”) (NASDAQ: APCX), a fintech company, today shared its Fourth Quarter 2024 financial results. The Company reported an operating loss of $2.1 million ($0.08 per share) versus a $3.4 million loss in the same quarter of 2023 ($0.18 per share). The operating loss for the full year 2024 was $8.8 million ($0.35 per share) versus $18.5 million ($1.01 per share) in 2023. CEO Thomas DeRosa noted that AppTech underwent significant organizational changes in the fourth quarter when a new investor group committed $5 million to improve the Company’s operations; established voting control of the Board of Directors and replaced certain key executives including the CEO and CFO. New CFO Felipe Corrado stated “We are encouraged by the organizational...

NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) — Brag House Holdings, Inc. (“Brag House” or the “Company”), a premier media technology platform designed for casual college gamers and brands seeking to connect with the Gen Z demographic, today announced the closing of its initial public offering (the “Offering”) of 1,475,000 shares of its common stock at a public offering price of US$4.00 per share. Kingswood Capital Partners, LLC is acting as the Sole Bookrunning Manager and WestPark Capital Inc. is acting as an underwriter. Lucosky Brookman LLP is acting as U.S. securities counsel to the Company, and Dickinson Wright LLP is acting as U.S. securities counsel to the underwriters in connection for the Offering. A registration statement on Form S-1 (File No. 333-280282) relating to the Offering was filed...